N/A N=15 Aspirin Responsiveness in Women With Coronary Artery Disease
CAD
Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease
Chronic Rhinosinusitis · Aspirin Exacerbated Respiratory Disease · Asthma
Primary: Urinary Levels of Cys-Leukotrienes — 874.05; 771.99 pg/ml
Early Phase 1 N=92 Aspirin Resistance in Coronary Artery Disease
Coronary Artery Disease
Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005
Phase 2 N=46 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Asthma, Aspirin-Induced · Aspirin Exacerbated Asthma
Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg
Phase 4 N=36 Aspirin Responsiveness in Women at Risk for Cardiac Events
Heart Disease
Primary: Number of Women Aspirin Resistant — 3 participants
N/A N=132 Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
Phase 4 N=70 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Cardiovascular Diseases · Metabolic Syndrome X · Atherosclerosis
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 2 N=54 Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Lung Carcinoma · Tobacco Use Disorder
Primary: Changes in Smoking-related Gene Expression Signature Score in Nasal Epithelium — -1.11; 1.39 gene expression signature score — p=0.04
Phase 4 N=13 Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Aspirin Sensitivity
Primary: Number of Participants Without Respiratory Reaction During Aspirin Desensitization — 0; 5 Participants — p=0.036
Phase 2 N=19 Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
Aspirin Exacerbated Respiratory Disease (AERD)
Primary: Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational…
N/A N=4 Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects
Healthy
Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
N/A N=9 Biosynthesis of PGD2 in Vivo
Hyperlipidemia
Primary: Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo — 95; 43 Percentage change…
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
Phase 2 N=27 The Effects of Omega-3 Fatty Acids on Aspirin Resistance
Increased Drug Resistance
Primary: the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment — 0.0; 10.9; -6.5; 30.5 seconds — p=0.00
Phase 4 N=72 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Acute Coronary Syndrome
Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml
Phase 3 N=12,546 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Moderate Risk of CVD
Primary: Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic…
Phase 4 N=244 Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
Cerebral Infarction
Primary: Aspirin Resistance (ARU ≥ 550) — 9; 11 participants — p=0.654
Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
Phase 4 N=302 Clopidogrel and Aspirin Interaction Study-2
Drug Action Increased
Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66
Phase 3 N=57 Aspirin in Young Psychotic Patients
Psychosis · Acute Psychosis · Schizophrenia
Primary: Neurological Soft Signs — 6.96; 7.04 score on a scale — p=0.863
Phase 2 N=36 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Nasal Polyps · Asthma, Aspirin-Induced · Aspirin-exacerbated Respiratory Disease
Primary: Provocative Dose 2 (PD2) During Aspirin Challenge — 121; 142 mg
Phase 1 N=102 Naproxen Sodium/ASA Platelet Study
Hematology
Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage
Phase 4 N=33 Pharmacogenomics of Antiplatelet Response - II (PARes-II)
Atherothrombosis
Primary: Changes in Platelet Transcriptome — 77.1 FPKM difference for HBG1 Gene
Phase 4 N=34 Pharmacogenomics of Antiplatelet Response
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
Phase 4 N=37 Aspirin Dose and Atherosclerosis in Patients With Heart Disease
Cardiovascular Diseases · Atherosclerosis · Myocardial Infarction
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL
Phase 4 N=36 Aspirin Dosing in Diabetic Patients
Type 2 Diabetes Mellitus · Coronary Artery Disease
Primary: Collagen Induced Aggregation — 32 percentage of platelet aggregation
N/A N=36 Comparative Effects of Aspirin and NHP-544C
Healthy
Primary: Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose — 0.181; 0.255 ng/mg creatinine